Preliminary evidence suggests that the multikinase inhibitor sorafenib has clinical activity in FLT3-ITD-positive (FLT3-ITD) acute myeloid leukemia (AML). However, the quality and sustainability of ...

Internal tandem duplication (ITD) mutation in Fms-like tyrosine kinase 3 gene (FLT3/ITD) represents an unfavorable genetic change in acute myeloid leukemia (AML) and is associated with poor prognosis.

Credit: Daiichi Sankyo. Vanflyta is expected to be available in the coming weeks. The Food and Drug Administration (FDA) has approved Vanflyta ® (quizartinib) in combination with standard cytarabine ...

A new type of targeting chaperon protein HSP70 inhibitor QL47 was recently discovered by a team led by Prof. LIU Qingsong from the Hefei Institutes of Physical Science (HFIPS) of the Chinese Academy ...

SAN DIEGO, April 22, 2025--(BUSINESS WIRE)--Invivoscribe is proud to announce that its wholly owned subsidiary, the Laboratory for Personalized Molecular Medicine ® (LabPMM), LLC has received approval ...

The illustration of protein structure (domains) on the left side, and corresponding exons in the FLT3 gene are displayed on the right side. FMS-like tyrosine kinase 3 (FLT3) mutations represent some ...

More Is Not Always Better: The Perils of Treatment Intensification in Pediatric Acute Lymphoblastic Leukemia A new question now confronts clinicians. A patient with FLT3-ITD AML who has successfully ...

Note: This article has been updated to reflect the correct revised PDUFA date. FDA has added 3 months to the review timeline for quizartinib, an investigational therapy for the treatment of adult ...

Genome-wide profiling of DNA copy number abnormalities in adult acute myeloid leukemia (AML) using high density single nucleotide polymorphism array No significant financial relationships to disclose.

Upregulation of FLT3 with internal tandem repeats (FLT3-ITD) occurs in approximately one quarter of patients with de novo acute myeloid leukemia (AML). Patients with FLT3-ITD often have more ...

There is a simple discount patient access scheme for quizartinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...